Combining Low Doses of Four Non-Psychoactive Cannabinoids Reduces Gut Pain in Mice with Colitis

Single injections of CBD or CBG (10 mg/kg) each reduced visceral hypersensitivity and spinal cord c-Fos activation in colitis mice. A combination of CBD (5 mg/kg) with CBC, CBDV, and CBG (each 1 mg/kg) — all at individually subtherapeutic doses — also reduced visceral pain. The combination acted through voltage-gated sodium and calcium channels (particularly Cav2.2) but not Cav3.2 or potassium channels.

Mouse model of dextran sulfate sodium colitis-induced visceral hypersensitivity. Single-injection cannabinoid administration. Patch-clamp electrophysiology on dorsal root ganglia neurons and recombinant ion channels to identify antinociceptive targets.

IBD patients frequently report abdominal pain as their most disabling symptom. This study demonstrates that a mixture of non-psychoactive cannabinoids can provide pain relief at doses where individual compounds are ineffective — a true entourage effect with identified molecular targets.

The entourage effect is often invoked but rarely demonstrated with specific mechanisms. This study provides concrete evidence that combining cannabinoids at low doses produces analgesic effects through identified ion channel targets, supporting multi-cannabinoid product development.

Mouse model of colitis may not fully recapitulate human IBD pain. Single-injection design does not assess chronic use. Subtherapeutic doses were defined within this model only. Did not reduce inflammation, only pain.